TAPUR Study Overview
The Targeted Agent and Profiling Utilization Registry (TAPURTM) Study offers a clinical trial opportunity for research collaborators to learn about the performance of specific targeted anti-cancer therapies in real-world patients. Seven pharmaceutical companies are collaborating with ASCO to provide:
- Access to study drugs at no cost to qualifying trial participants
- Support for research sites to conduct the study
- Infrastructure support for ASCO study administration and site participation.
How the TAPUR Study Works
The TAPUR Study is open and enrolling patients at 113 clinical sites. Most of the clinical sites are part of a larger network, and all questions and/or referrals should be directed to the primary contact at the main operations center.
Collaborating Pharmaceutical Companies
ASCO acknowledges the following companies for their collaboration and support of the TAPUR Study:
- Bristol-Myers Squibb
- Eli Lilly and Company
Companies interested in more information or participating in the TAPUR Study may contact the TAPUR team.
Genomic Testing Labs
Eligible patients must have an advanced cancer with a potentially actionable genomic alteration that can be targeted with a TAPUR Study drug. The study requires testing in a lab that is certified under federal requirements (the Clinical Laboratory Improvement Amendments, or CLIA), accredited by New York State (for laboratories offering services to residents of New York), and accredited by the College of American Pathologists.
In addition, the following labs have sought an ASCO designation that recognizes that they provide a test that is optimized for TAPUR Reporting:
- Caris Life Sciences®
- Foundation Medicine, Inc.
This designation is provided to laboratories that:
- Test for and report on at least 75% of the TAPUR genomic alterations*
- Creates reports that specifically identify the TAPUR Study genes, which can be sent to TAPUR Study clinical centers.
*If this condition is not met, additional restrictions apply.
Laboratories interested in obtaining this designation may contact the TAPUR team.
Disclaimer: Neither the American Society of Clinical Oncology, the TAPUR Study, nor any of their affiliates endorse, support, or oppose any particular product, service, organization, treatment option, or other matter. The mention of any product, service, organization, activity, or therapy on this website, or the designation of a laboratory’s reporting as being optimized for TAPUR reporting, should not be construed as an ASCO endorsement.
TAPUR Study News & Updates
View the latest study news, including links to press releases, information on study progress, and timely updates of interim cohort analyses and closures.